CA2904743A1 - Anticorps diriges contre hgf et compositions les contenant - Google Patents

Anticorps diriges contre hgf et compositions les contenant Download PDF

Info

Publication number
CA2904743A1
CA2904743A1 CA2904743A CA2904743A CA2904743A1 CA 2904743 A1 CA2904743 A1 CA 2904743A1 CA 2904743 A CA2904743 A CA 2904743A CA 2904743 A CA2904743 A CA 2904743A CA 2904743 A1 CA2904743 A1 CA 2904743A1
Authority
CA
Canada
Prior art keywords
seq
sequence
antibody
variable heavy
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2904743A
Other languages
English (en)
Inventor
Benjamin H. Dutzar
Katie ANDERSON
Brian R. Kovacevich
Andrew L. Feldhaus
John A. Latham
Leon F. Garcia-Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck Seattle Biopharmaceuticals Inc
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of CA2904743A1 publication Critical patent/CA2904743A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps et des fragments de ceux-ci ayant une spécificité de liaison pour HGF. Un autre mode de réalisation de cette invention concerne les anticorps décrits ici, et des fragments de liaison de ceux-ci, comprenant les séquences des polypeptides VH, VL et CDR décrits dans la description, et les polynucléotides codant pour ceux-ci. L'invention concerne également des conjugués d'anticorps anti-HGF et des fragments de liaison de ceux-ci conjugués à une ou plusieurs fractions fonctionnelles ou détectables. L'invention concerne également des procédés de fabrication desdits anticorps anti-HGF et des fragments de liaison associés. Des modes de réalisation de l'invention concernent également l'utilisation d'anticorps anti-HGF, et des fragments de liaison de ceux-ci, pour le diagnostic, l'estimation et le traitement de maladies et de troubles associés à HGF.
CA2904743A 2013-03-14 2014-03-14 Anticorps diriges contre hgf et compositions les contenant Abandoned CA2904743A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781643P 2013-03-14 2013-03-14
US201361782868P 2013-03-14 2013-03-14
US61/782,868 2013-03-14
US61/781,643 2013-03-14
PCT/US2014/029163 WO2014153117A2 (fr) 2013-03-14 2014-03-14 Anticorps dirigés contre hgf et compositions les contenant

Publications (1)

Publication Number Publication Date
CA2904743A1 true CA2904743A1 (fr) 2014-09-25

Family

ID=51581767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904743A Abandoned CA2904743A1 (fr) 2013-03-14 2014-03-14 Anticorps diriges contre hgf et compositions les contenant

Country Status (7)

Country Link
EP (1) EP2964673A4 (fr)
JP (1) JP2016516052A (fr)
KR (1) KR20150140685A (fr)
CN (1) CN105246915A (fr)
CA (1) CA2904743A1 (fr)
TW (2) TW201444868A (fr)
WO (2) WO2014153166A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699868B (zh) * 2017-03-01 2019-11-15 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN121197419A (zh) * 2019-09-30 2025-12-26 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
KR20220098755A (ko) 2019-11-05 2022-07-12 애브비 인코포레이티드 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘
WO2022228514A1 (fr) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 Anticorps anti-facteur inhibiteur de la leucémie humaine et son utilisation
WO2024129564A1 (fr) * 2022-12-13 2024-06-20 The Children's Medical Center Corporation Méthodes et compositions pour le traitement d'anomalies vasculaires
KR20250058158A (ko) * 2023-10-20 2025-04-30 주식회사 셀랩메드 암 치료용 약제학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2021463B1 (fr) * 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Procédé de culture permettant d'obtenir une population clonée de lymphocytes b spécifiques d'antigène
CN101460520B (zh) * 2006-06-02 2012-12-26 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US7649083B2 (en) * 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9539324B2 (en) * 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Also Published As

Publication number Publication date
WO2014153117A2 (fr) 2014-09-25
WO2014153166A2 (fr) 2014-09-25
WO2014153117A3 (fr) 2015-01-08
WO2014153117A9 (fr) 2014-11-27
KR20150140685A (ko) 2015-12-16
CN105246915A (zh) 2016-01-13
WO2014153166A3 (fr) 2014-12-04
TW201444868A (zh) 2014-12-01
JP2016516052A (ja) 2016-06-02
EP2964673A4 (fr) 2017-02-22
TW201438737A (zh) 2014-10-16
EP2964673A2 (fr) 2016-01-13

Similar Documents

Publication Publication Date Title
US20190085066A1 (en) Antibodies to hgf and compositions containing
US9783603B2 (en) Therapeutic use of antibodies to HGF
US20140271464A1 (en) Therapeutic use of antibodies to hgf
CA2904743A1 (fr) Anticorps diriges contre hgf et compositions les contenant
JP6412543B2 (ja) Ｉｌ−６に対する抗体およびその使用
RS63063B1 (sr) Anti-ngf antitela i njihova upotreba
AU2015237275A1 (en) Antibodies that bind human cannabinoid 1 (CB1) receptor
CA3174442A1 (fr) Anticorps anti-cd36 et leur utilisation pour traiter le cancer
EP4001306A1 (fr) Anticorps monoclonal anti-vegf humanisé
EP2686016B1 (fr) Anticorps de reconnaissance de domaine n-terminal de midkine
US20230183379A1 (en) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2021032174A1 (fr) Protéine de liaison à l'antigène anti-cd47 et son utilisation
US11365250B2 (en) Compositions and methods for cancer therapy
EP4186526A1 (fr) Agent pour inverser la résistance à des médicaments anticancéreux
EA052734B1 (ru) СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
HK1240945B (en) Antibodies to il-6 and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190311

FZDE Discontinued

Effective date: 20220506